about
Vgf is a novel biomarker associated with muscle weakness in amyotrophic lateral sclerosis (ALS), with a potential role in disease pathogenesisNeuropeptides in depression: role of VGFThe role of the vgf gene and VGF-derived peptides in nutrition and metabolismChaperones in NeurodegenerationNew developments and future opportunities in biomarkers for amyotrophic lateral sclerosisAn inducer of VGF protects cells against ER stress-induced cell death and prolongs survival in the mutant SOD1 animal models of familial ALSThe neuroendocrine protein 7B2 is intrinsically disorderedThe neuroendocrine protein 7B2 suppresses the aggregation of neurodegenerative disease-related proteinsCystatin C: a candidate biomarker for amyotrophic lateral sclerosisMonitoring CSF proteome alterations in amyotrophic lateral sclerosis: obstacles and perspectives in translating a novel marker panel to the clinicVGF Protein and Its C-Terminal Derived Peptides in Amyotrophic Lateral Sclerosis: Human and Animal Model StudiesAmyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cellsMALDI imaging of post-mortem human spinal cord in amyotrophic lateral sclerosis.Proteomic analysis of plasma from Portuguese patients with familial amyotrophic lateral sclerosis.Methodological deficits in diagnostic research using '-omics' technologies: evaluation of the QUADOMICS tool and quality of recently published studiesComparative proteomic profiling of cerebrospinal fluid between living and post mortem ALS and control subjects.Applying proteomics to the diagnosis and treatment of ALS and related diseases.Alzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: experimental approaches and future clinical applications.Serum Nogo-A levels are not elevated in amyotrophic lateral sclerosis patients.Intricate effects of primary motor neuronopathy on contractile proteins and metabolic muscle enzymes as revealed by label-free mass spectrometry.A novel unbiased proteomic approach to detect the reactivity of cerebrospinal fluid in neurological diseasesBiomarkers in frontotemporal lobar degenerations--progress and challenges.Identification of a novel biomarker candidate, a 4.8-kDa peptide fragment from a neurosecretory protein VGF precursor, by proteomic analysis of cerebrospinal fluid from children with acute encephalopathy using SELDI-TOF-MSBiomarker discovery in neurodegenerative diseases: a proteomic approach.Proteomic pattern analysis discriminates among multiple sclerosis-related disorders.Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomicsNovel CSF biomarkers for frontotemporal lobar degenerations.Neuroproteomics: an insight into ALS.Protective mechanisms by cystatin C in neurodegenerative diseases.The expression of VGF is reduced in leukocytes of depressed patients and it is restored by effective antidepressant treatment.Proteomic Characterization of Cerebrospinal Fluid from Ataxia-Telangiectasia (A-T) Patients Using a LC/MS-Based Label-Free Protein Quantification Technology.Evidence for fungal infection in cerebrospinal fluid and brain tissue from patients with amyotrophic lateral sclerosis.On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia.Measurement of cystatin C levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis.New considerations in the design of clinical trials for amyotrophic lateral sclerosisCystatin C in Alzheimer's disease.Assessment of a multiple biomarker panel for diagnosis of amyotrophic lateral sclerosis.Molecular signatures of amyotrophic lateral sclerosis disease progression in hind and forelimb muscles of an SOD1(G93A) mouse modelChanges of Cerebrospinal Fluid Peptides due to Tauopathy.CSF proteomic fingerprints for HIV-associated cognitive impairment.
P2860
Q24644968-98C27B90-56A1-40C5-AA28-0CCD88BF61E5Q24647788-6F61B00B-C0E1-4911-8E2C-2233DCB9E538Q24657048-A1E34B13-B08A-4D06-A4BE-7DD1B81B18F1Q26782943-A5A3EE02-3DA2-43EC-9AC6-11FCC8095902Q26783410-6207A80D-F584-42E9-A877-C45CCF5A884CQ27312650-BCB04474-A25D-496C-8669-14C139ECBC72Q28274203-57850886-85AA-42F8-B133-AF4CE44129A9Q28279676-7AE3E54F-FC46-47CA-B505-6231865E3F20Q28476466-8FDE12C3-14F9-4632-A544-45F6000117CFQ28483618-0B899453-2225-4664-904A-6C941E646648Q28554689-10400A4E-6434-4AD0-B043-FA34C605ABC8Q28744223-AEF15894-2A77-40F7-9A6B-DFEFF5FC8137Q31096152-63B5D687-730B-44F3-A7E2-4F80E4C9DB15Q33349895-AC15836A-00B2-4A77-8831-8DF120CB84D5Q33631197-06817473-476C-4947-BA97-C2956B023D80Q33691896-1759D518-FC04-407A-937B-4E7F483EE9FDQ33719446-F0B19C76-7072-4709-965D-EE1DA8F1EC71Q33736582-F561AD67-7834-4A26-9FEC-F00FF07EDB1AQ33741393-29F90030-2068-483B-97A4-5DA4F1197D6FQ33827791-71D33DC6-942A-4FFA-8CC8-E592391DA8B6Q33851008-0900512F-3A9E-4E6F-AD7F-0F83E6212513Q33893515-08C57B55-A3AA-4EAB-9918-FE495E6FF3D9Q33992022-E230A63C-6D73-4C9B-970E-0A2FA52DD7A3Q34125681-BD9E4047-2DFA-463F-B18D-67CB4E1860B1Q34241223-7CCCEFE3-7012-4824-B862-97AF59291E99Q34285662-02FFE5C1-ACEE-42EA-91E3-98C54BF4697EQ34370894-ACBDB8FD-5FAB-4EFD-8EE0-5F77C59F782BQ34475101-FD26AECE-21DC-42A3-8941-9C40AF745911Q34572391-18A5F9E9-9ACD-4A8A-B311-BA96B3497282Q34661044-3164FA02-CA88-497B-BB5F-8171FD506299Q35432364-EB1999C1-F8DA-4428-B121-D01AE1489E75Q35451557-A926348E-6C49-49E6-AAFA-DDF59CD996ECQ35592875-72440D5F-39BA-44EB-BE7A-9C5562BAD3B3Q35854192-C8506FC5-530E-4667-B6CE-EBA50E3A0618Q35910744-B48C822D-0A1B-4A40-9546-CD79E1908172Q36078684-38CE4AA0-B244-4CDD-94C2-AD41199C0228Q36135242-55502D8D-AF38-4649-8DE5-D78B10B61360Q36218785-66CD07B5-E5A9-474F-BC01-7CD37B0276F4Q36357894-9A6DEBF0-114F-416A-80FE-5CA8266D68E9Q36470218-4CA8A050-DB49-4794-8213-B7F428B5D572
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Identification of potential CSF biomarkers in ALS.
@ast
Identification of potential CSF biomarkers in ALS.
@en
type
label
Identification of potential CSF biomarkers in ALS.
@ast
Identification of potential CSF biomarkers in ALS.
@en
prefLabel
Identification of potential CSF biomarkers in ALS.
@ast
Identification of potential CSF biomarkers in ALS.
@en
P2093
P1433
P1476
Identification of potential CSF biomarkers in ALS.
@en
P2093
Cudkowicz ME
Pasinetti GM
P304
P356
10.1212/01.WNL.0000203129.82104.07
P407
P577
2006-02-15T00:00:00Z